1. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
- Author
-
Devendra Hiwase, Christopher Hahn, Elizabeth Ngoc Hoa Tran, Rakchha Chhetri, Anmol Baranwal, Aref Al-Kali, Kirsty Sharplin, Dariusz Ladon, Rachel Hollins, Patricia Greipp, Monika Kutyna, Hassan Alkhateeb, Talha Badar, Paul Wang, David M. Ross, Deepak Singhal, Naranie Shanmuganathan, Peter Bardy, Ashanka Beligaswatte, David Yeung, Mark R. Litzow, Abhishek Mangaonkar, Pratyush Giri, Cindy Lee, Angie Yong, Noemi Horvath, Nimit Singhal, Raghu Gowda, William Hogan, Naseema Gangat, Mrinal Patnaik, Kebede Begna, Ing S. Tiong, Andrew Wei, Sharad Kumar, Anna Brown, Hamish Scott, Daniel Thomas, Chung H. Kok, Ayalew Tefferi, Mithun Vinod Shah, Hiwase, Devendra, Hahn, Christopher, Tran, Elizabeth Ngoc Hoa, Chhetri, Rakchha, Wang, Paul, Kumar, Sharad, Brown, Anna, Scott, Hamish, Kok, Chung H, and Shah, Mithun Vinod
- Subjects
Immunology ,TP53 mutation ,Cell Biology ,Hematology ,acute myeloid leukemia ,high-throughput nucleotide sequencing ,Biochemistry ,Bohring Syndrome - Published
- 2022